Research programme: antifungal therapeutics - SelmodAlternative Names: AB 284
Latest Information Update: 29 Jul 2016
At a glance
- Originator Selmod
- Class Anti-infectives; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Mycoses
Most Recent Events
- 20 Jul 2016 Early research in Mycoses in Switzerland (unspecified route) before July 2016
- 10 Feb 2016 AB 284 has patent protection (Selmod Presentation, February 2016)